sponsored
PatientsVille.com Logo

PatientsVille

Lubiprostone Medical Research Studies

Up-to-date List of Lubiprostone Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lubiprostone Medical Research Studies

Rank Status Study
1 Unknown  Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
Conditions: Multiple Sclerosis;   Constipation
Interventions: Drug: Lubiprostone;   Drug: Placebo
Outcome Measures: To determine the effect of Lubiprostone 24 mcg twice daily on spontaneous bowel movements in patients with MS-associated constipation;   To determine the safety of Lubiprostone based on adverse event (AE) type, frequency, and severity. Hypothesis: AE type, frequency, and severity will be comparable in Lubiprostone and placebo treated patients.
2 Unknown  Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Condition: Chronic Constipation, Methanogenesis
Interventions: Drug: Lubiprostone;   Drug: Lubiprostone Control
Outcome Measure: Effect of Lubiprostone in patients with Chronic Constipation
3 Recruiting The Effectiveness of Lubiprostone in Constipated Diabetics
Conditions: Constipation;   Diabetes
Intervention: Drug: Lubiprostone
Outcome Measures: The primary efficacy measure is number spontaneous bowel movements (SBMs) per week;   Colonic transit time in hours as measured SmartPill pH Capsule;   Presence and severity of daily abdominal discomfort;   Quality of life;   Adherence
4 Recruiting Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Persons With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Condition: HIV
Intervention: Drug: Lubiprostone
Outcome Measures: Change in CD8+ T-cell activation;   Change in gut microbial translocation;   Change from baseline in CD8+ T-cell activation;   Change from baseline in CD4+ T-cell activation;   Change in levels of systemic inflammation;   Change in plasma HIV-1 RNA;   Change in peripheral CD4+;   Change in Act1 Antibody;   Gut microbiome;   Safety
5 Recruiting Long-term Safety and Efficacy of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Condition: Constipation - Functional
Intervention: Drug: Lubiprostone
Outcome Measures: Evaluation of incidence of adverse events (AEs);   Evaluation of changes in clinical laboratory parameters;   Evaluation of changes in physical examination;   Evaluation of changes in vital sign measurements;   Assessment of bone mineral density and bone mineral content;   Changes from baseline in bowel movement (BM) and spontaneous bowel movement (SBM) frequency rate;   Changes from baseline in stool consistency of SBMs.;   Monthly SBM Response;   Treatment effectiveness rating;   Overall Health-related quality of life (PedsQL™);   Change from baseline in incontinence episodes frequency;   Change from baseline in the production of large diameter stool;   Change from baseline in frequency of faecal impaction;   Change from baseline in proportion of BMs and SBMs in toilet overall;   Change from baseline in frequency of retentive posturing or excessive volitional stool retention;   Changes from baseline in straining associated with SBMs.;   Changes from baseline in abdominal pain associated with SBMs.;   Changes from baseline in constipation severity.
6 Recruiting Efficacy and Safety of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Condition: Constipation - Functional
Interventions: Drug: Lubiprostone;   Drug: Placebo
Outcome Measures: Overall spontaneous bowel movement (SBM) response;   Overall change from baseline in SBM frequency across the 12-week treatment period;   Monthly SBM responder rates;   Overall change from baseline in bowel movement (BM) and SBM frequency;   Time to first SBM;   Changes from baseline in straining associated with SBMs, stool consistency of SBMs, abdominal pain, constipation severity, and treatment effectiveness;   Overall health-related quality of life;   Treatment response;   Change from baseline in incontinence episodes frequency;   Change from baseline in the production of large diameter stool;   Frequency of faecal impaction;   Proportion of BMs and SBMs in toilet;   Frequency of retentive posturing or excessive volitional stool retention;   Percentage of subjects with an SBM within 4, 8, 12, 24 and 48 hours of first study medication administration

These studies may lead to new treatments and are adding insight into Lubiprostone etiology and treatment.

A major focus of Lubiprostone research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Lubiprostone